Investment Thesis

.

Competitive Moat

primarily built on intangible assets, including proprietary technology, strong brand recognition, and regulatory advantages. The company's extensive patents and FDA approvals create high barriers to entry for competitors, ensuring a durable advantage over the next 5-10 years. The main competitive threats are emerging players in the minimally invasive cardiac space, such as Abbott Laboratories, and established firms diversifying into structural heart solutions, such as Medtronic.

Growth Engine

Future revenue growth for EW is driven by a total addressable market (TAM) exceeding $10 billion, primarily from its transcatheter heart valve replacement products, which are expected to capture an increasing share of the cardiac surgery market. The company is well-positioned to benefit from organic growth as demand for minimally invasive procedures rises globally, particularly in Europe and Asia-Pacific, where healthcare systems are increasingly adopting advanced technologies. Recent product launches, including the PASCAL and Cardioband systems, enhance market share, bolstered by continuous innovation and a strong pipeline of new offerings.